Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 4, 1999, Pages 338-345

  Johne, Andreas ^b   Brockmöller, Jürgen ^b   Bauer, Steffen ^b   Maurer, Agathe ^b   Langhcinrich, Matthias ^b   Roots, Ivar ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG TRANSPORT; FEMALE; FRUIT; HUMAN; HYPERICUM PERFORATUM; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; ANTI-ARRHYTHMIA AGENTS; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; CARDIOTONIC AGENTS; DIGOXIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERICUM; MALE; PHYTOTHERAPY; PLANTS, MEDICINAL; REFERENCE VALUES; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 0000006828     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.a101944     Document Type: Article

References (29)

1. 1. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression: an overview and meta-analysis of randomised trials. BMJ 1996;313:253-8.
2. 2. Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D, editors. Arzneimittelreport 1998. Berlin: Springer Verlag; 1998. p. 454-78.
3. 3. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997;30(suppl):129-34.
4. 4. Brockmöller J, Reum T, Bauer S, Kerb R, Hübner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30(suppl):94-101.
5. 5. Kerb R, Brockmöller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996;40:2087-93.
6. 6. Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of hypericin: a compound with a broad spectrum of biological activities. Med Res Rev 1995;15:111-9.
7. 7. Diwu Z. Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochem Photobiol 1995; 61:529-39.
8. 8. Obermeier MT, White RE, Yang CS. Effects of bioflavonoids on hepatic P450 activities. Xenobiotica 1995;25:575-84.
9. 9. Song D, Lorenzo B, Reidenberg MM. Inhibition of 11 beta-hydroxysteroid dehydrogenase by gossypol and bioflavonoids. J Lab Clin Med 1992;120:792-7.
10. 10. Walle T, Eaton EA, Walle UK. Quercetin, a potent and specific inhibitor of the human P-form phenolsulfotransferase. Biochem Pharmacol 1995;50:731-4.
11. 11. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998;63: 499-510.
12. 12. Cohen AF, Kroon R, Schoemaker HC, Breimer DD, van Vliet-Verbeek A, Brandenburg HC. The bioavailability of digoxin from three oral formulations measured by a specific hplc assay. Br J Clin Pharmacol 1993;35:136-42.
13. 13. Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988;15:227-44.
14. 14. Kerb R, Bauer S, Brockmöller J, Roots I. Urinary 6β-hydroxycortisol excretion rate is affected by treatment with hypericum extract [abstract]. Eur J Clin Pharmacol 1997;52(suppl): A186.
15. 15. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St John's wort and theophylline [letter]. Ann Pharmacother 1999;33:502.
16. 16. Lacarelle B, Rahmani R, de Sousa G, Durand A, Placidi M, Cano JP. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 1991;5:567-82.
17. 17. Gault H, Kalra J, Ahmed M, Kepkay D, Barrowman J. Influence of gastric pH on digoxin biotransformation; I: intragastric hydrolysis. Clin Pharmacol Ther 1980; 27:16-21.
18. 18. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, el al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53.
19. 19. Rameis H. On the interaction between phenytoin and digoxin. Eur J Clin Pharmacol 1985;29:49-53.
20. 20. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, Borst P. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-705.
21. 21. Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996;24:142-7.
22. 22. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64:123-8.
23. 23. Salphati L, Benet LZ. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 1998;55:387-95.
24. 24. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-14.
25. 25. Hu XF, Slater A, Rischin D, Kantharidis P, Parkin JD, Zalcberg J. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer 1999;79:831-7.
26. 26. Kuhlmann J, Zilly W, Wilke J. Fffects of cytostatic drugs on plasma level and renal excretion of beta-acetyldigoxin. Clin Pharmacol Ther 1981;30:518-27.
27. 27. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 1998;95:9831-6.
28. 28. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1999;16: 478-85.
29. 29. Maurer A, Johne A, Bauer S, Brockmöller J, Donath F, Roots I, et al. Interaction of St John's wort extract with phenprocoumon [abstract]. Eur J Clin Pharmacol 1999; 55:A22.